[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1235
31. Scalcione LR, Katz DS, Santoro MS, Mahboob S, Badler RL, Yung EY: Primary testicular lymphoma involving the spermatic cord and gonadal vein. Clin Nucl Med; 2009 Apr;34(4):222-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 70-year-old man with a history of prostatic adenocarcinoma and a 3-month history of right hemiscrotal swelling.
  • The patient underwent a CT scan, scrotal ultrasound, and F-18 FDG-PET scan to evaluate for metastatic prostate cancer.
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / radionuclide imaging. Spermatic Cord / pathology. Testicular Neoplasms / diagnosis. Testicular Neoplasms / radionuclide imaging. Testis / blood supply. Veins / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300051.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, Ghikonti I: Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology; 2005 Oct;66(4):897-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
  • OBJECTIVES: To identify neuroendocrine cells and androgen receptors (ARs), possible predictors of cancer progression, in a series of untreated patients with incidental Stage T1a prostate cancer (PCa).
  • The AR is thought to have a central role in the propagation of prostate carcinogenesis.
  • The patients were followed up for a mean of 63.9 months, and a subsequent rise in prostate-specific antigen or positive digital rectal examination findings confirmed by biopsy was considered disease progression.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / pathology. Receptors, Androgen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230178.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Receptors, Androgen
  •  go-up   go-down


33. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY: AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer; 2005 Jul;43(3):249-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer.
  • Expression of AGR2 mRNA was specifically detected in limited human tissue rich in epithelial cells, including the prostate gland.
  • Analysis of 46 microdissected primary prostate adenocarcinoma samples showed that AGR2 mRNA expression was markedly elevated in the majority of tumors as compared to matched adjacent benign tissues.
  • Immunohistochemistry analysis indicated that AGR2 protein expression was highly restricted to the secretory epithelial cells in the prostate gland.
  • In tissue sections from radical prostatectomy specimens, immunohistochemical staining of AGR2 showed markedly increased expression in high-grade prostatic intraepithelial neoplasia and Gleason pattern 3-4 prostatic adenocarcinoma.
  • Therefore, the androgen-induced secretory protein AGR2 may serve as a potential therapeutic target and/or molecular marker for prostate cancer.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics. Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Amino Acid Sequence. Animals. Base Sequence. Cloning, Molecular. Humans. Immunohistochemistry. Male. Metribolone / pharmacology. Molecular Sequence Data. Prostate / physiology. Protein Biosynthesis. Protein Disulfide-Isomerases. RNA, Messenger / genetics. Sequence Alignment. Sequence Homology, Amino Acid. Testosterone Congeners / pharmacology. Transcription, Genetic. Xenopus. Xenopus Proteins / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15834940.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA70892; United States / NCI NIH HHS / CA / CA91956.2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger; 0 / Testosterone Congeners; 0 / Xenopus Proteins; 2C323EGI97 / Metribolone; EC 5.3.4.1 / AGR2 protein, human; EC 5.3.4.1 / Protein Disulfide-Isomerases; EC 5.3.4.1 / XAG-2 protein, Xenopus
  •  go-up   go-down


3
Advertisement
4. Gerogianni I, Gravas S, Papadopoulos D, Terzis A, Nakou M, Tzortzis V, Gourgoulianis K, Melekos MD: Endobronchial metastasis from prostate cancer. Int Urol Nephrol; 2008;40(4):961-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastasis from prostate cancer.
  • We report a case of endobronchial metastasis from prostate adenocarcinoma.
  • A patient with a history of prostate cancer under complete androgen blockade presented to the respiratory department complaining of dyspnea and dry coughing.
  • Flexible bronchoscopy showed multiple polypoid lesions in the tracheobronchial tree and the immunohistochemical studies on the biopsy specimen determined the diagnosis.
  • To our knowledge, this is the first case of endobronchial metastasis of a patient with androgen refractory prostate cancer without any evidence of extrathoracic metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Bronchial Neoplasms / secondary. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1986;8(4):319-24 [3714573.001]
  • [Cites] Int Urol Nephrol. 2004;36(4):555-7 [15787335.001]
  • [Cites] Int Urol Nephrol. 2007;39(2):537-9 [17308872.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Sep;106(3):537-42 [8361198.001]
  • [Cites] J Surg Oncol. 1996 Aug;62(4):249-52 [8691837.001]
  • [Cites] Acta Oncol. 2004;43(1):73-9 [15068323.001]
  • [Cites] Strahlenther Onkol. 2002 Aug;178(8):442-5 [12240550.001]
  • [Cites] Thorax. 1990 Jan;45(1):66-7 [2138826.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):641-5 [1700598.001]
  • [Cites] Lung Cancer. 2000 May;28(2):163-70 [10717334.001]
  • [Cites] Int Urol Nephrol. 2008;40(3):675-8 [18085425.001]
  • [Cites] Ann Thorac Surg. 1988 Feb;45(2):223-4 [3341829.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(3):293-5; discussion 295 [15897914.001]
  • [Cites] Br J Radiol. 1999 Oct;72 (862):933-41 [10673942.001]
  • (PMID = 18368505.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 35LT29625A / Estramustine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Fitzgerald TJ, Wang T, Goel HL, Huang J, Stein G, Lian J, Davis RJ, Doxsey S, Balaji KC, Aronowitz J, Languino LR: Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Rev Anticancer Ther; 2008 Jun;8(6):967-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.
  • Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men.
  • Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):433-42 [14755675.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Biol. 2004 Aug 2;166(3):407-18 [15289498.001]
  • [Cites] Radiat Res. 1992 Jun;130(3):281-8 [1594753.001]
  • [Cites] Adv Cancer Res. 1996;68:183-223 [8712068.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2203-9 [10232609.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):99-111 [10388524.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1859-66 [15547727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1454-9 [15665096.001]
  • [Cites] J Cell Biol. 2000 May 1;149(3):741-54 [10791986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1676-81 [11172010.001]
  • [Cites] Mol Pathol. 2001 Jun;54(3):133-7 [11376123.001]
  • [Cites] Trends Mol Med. 2001 Dec;7(12):542-7 [11733216.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26321-6 [12015321.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4263-72 [12154028.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44969-79 [12297496.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):6702-9 [12493743.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 7;311(1):174-8 [14575710.001]
  • [Cites] Int J Radiat Biol. 2003 Sep;79(9):709-20 [14703944.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):376-87 [15864279.001]
  • [Cites] Prostate. 2005 Jun 15;64(1):83-91 [15651037.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1378-90 [16247454.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2339-48 [16331261.001]
  • [Cites] Laryngoscope. 2006 Jul;116(7):1228-31 [16826065.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 22;351(3):726-32 [17087916.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):163-80 [17084981.001]
  • [Cites] Nature. 2007 Jan 25;445(7126):442-6 [17251981.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):652-61 [16909121.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1155-62 [17283150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3189-94 [17360627.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):142-9 [17303404.001]
  • [Cites] J Pathol. 2007 Jul;212(3):316-24 [17503414.001]
  • [Cites] Int J Radiat Biol. 2007 Nov-Dec;83(11-12):761-7 [18058365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19861-6 [18077419.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):43-52 [14965266.001]
  • (PMID = 18533806.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089720; United States / NCI NIH HHS / CA / R01 CA-89720; United States / NCI NIH HHS / CA / R01 CA109874; United States / NCI NIH HHS / CA / R01 CA109874-04; United States / NCI NIH HHS / CA / R01 CA089720-05; United States / NCI NIH HHS / CA / CA089720-04; United States / NCI NIH HHS / CA / CA089720-05; United States / NCI NIH HHS / CA / R56 CA089720; United States / NCI NIH HHS / CA / R01 CA089720-04; United States / NCI NIH HHS / CA / R01 CA-109874; United States / NCI NIH HHS / CA / CA109874-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 40
  • [Other-IDs] NLM/ NIHMS128881; NLM/ PMC2764989
  •  go-up   go-down


36. Zorn KC, Gofrit ON, Steinberg GD, Shalhav AL: Evolution of robotic surgery in the treatment of localized prostate cancer. Curr Treat Options Oncol; 2007 Jun;8(3):197-210
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of robotic surgery in the treatment of localized prostate cancer.
  • Adenocarcinoma of the prostate is the second most common cancer in men in the United States (following only skin cancer) and accounts for 33% of all newly diagnosed male cancers.
  • It is estimated that in 2007, 218,890 men will be diagnosed with prostate cancer and 27,050 will die from this disease.
  • While most currently diagnosed prostate cancers are localized, radical prostatectomy remains a gold standard treatment.
  • With its development in the late 1990s, minimally invasive surgery has significantly and irrevocably changed the surgical treatment of prostate cancer.
  • Robotic-assisted laparoscopic radical prostatectomy allows patients the benefits of minimally invasive surgery with functional and oncological results comparable to those from open and standard laparoscopic procedures, we believe that this surgical approach will shortly evolve into the standard surgical approach for localized prostate cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatectomy / methods. Prostatic Neoplasms / surgery


37. Bonkhoff H: [Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry]. Pathologe; 2005 Nov;26(6):405-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry].
  • [Transliterated title] Differenzialdiagnose des Prostatakarzinoms. Rolle der Mustererkennung und der Immunhistochemie.
  • Prostate cancer offers a wide range of growth patterns depicted in the classical Gleason diagram.
  • For each Gleason pattern exist a number of benign and malignant mimickers that can simulate prostatic adenocarcinoma.
  • In the present review, the use of immunohistochemical markers is discussed with emphasis to a pattern-based approach to differential diagnosis in prostate pathology.
  • AMACR (P504 s) is helpful not only in identifying small amount of cancer in needle biopsies but also in the diagnosis of high grade prostatic intra epithelial neoplasia (HGPIN).
  • A number of lesions which may be confused with small acinar adenocarcinoma (Cowper's gland, nephrogenic metaplasia, mesonephric glands) and poorly differentiated prostate cancer (urothelial neoplasia, mucinous colon cancer and other metastatic lesions) lacks convincing PSA immunoreactivity.
  • Basal cell markers and the nuclear androgen receptors are important markers to differentiate Gleason grade 5 A und 5 B patterns from prostatic involvement by transitional cell carcinoma.
  • Finally, a selected panel of markers is useful to classify prostatic stromal lesions.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Cell Division / physiology. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology


38. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ: Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res; 2008 May 15;68(10):3601-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of p57Kip2 induces prostate cancer in the mouse.
  • However, little is known about the role of p57(Kip2) in tumorigenesis and cancer progression.
  • Here, we show that the expression of p57(Kip2) is significantly decreased in human prostate cancer, and the overexpression of p57(Kip2) in prostate cancer cells significantly suppressed cell proliferation and reduced invasive ability.
  • In addition, overexpression of p57(Kip2) in LNCaP cells inhibited tumor formation in nude mice, resulting in well-differentiated squamous tumors rather than adenocarcinoma.
  • Furthermore, the prostates of p57(Kip2) knockout mice developed prostatic intraepithelial neoplasia and adenocarcinoma.
  • Remarkably, this mouse prostate cancer is pathologically identical to human prostate adenocarcinoma.
  • Therefore, these results strongly suggest that p57(Kip2) is an important gene in prostate cancer tumorigenesis, and the p57(Kip2) pathway may be a potential target for prostate cancer prevention and therapy.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p57 / biosynthesis. Down-Regulation. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483241.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA116097; United States / NCI NIH HHS / CA / R01-CA76142
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1c protein, mouse; 0 / Cyclin D; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Cyclins; 0 / Retinoblastoma Protein; EC 2.7.11.22 / Cdk2 protein, mouse; EC 2.7.11.22 / Cdk4 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


39. Wohlmuth H, Deseo MA, Brushett DJ, Thompson DR, Macfarlane G, Stevenson LM, Leach DN: Diarylheptanoid from Pleuranthodium racemigerum with in vitro prostaglandin E(2) inhibitory and cytotoxic activity. J Nat Prod; 2010 Apr 23;73(4):743-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The compound also demonstrated cytotoxic activity against the P388D1 murine lymphoblast cell line (IC(50) = 117.0 microM) and four human cell lines: Caco-2 colonic adenocarcinoma (IC(50) = 44.8 microM), PC3 prostate adenocarcinoma (IC(50) = 23.6 microM), HepG2 hepatocyte carcinoma (IC(50) = 40.6 microM), and MCF7 mammary adenocarcinoma (IC(50) = 56.9 microM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20297825.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diarylheptanoids; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


40. Liauw SL, Weichselbaum RR, Rash C, Correa D, Al-Hallaq HA, Pelizzari CA, Jani AB: Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat; 2009 Jun;8(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer.
  • Intensity modulated radiation therapy (IMRT) has achieved widespread use for prostate cancer; however, in relation to this use, outcomes studies are still relatively sparse.
  • We report a single-institutional experience in outcomes analysis with the use of IMRT for the primary management of prostate cancer.
  • One hundred thirty consecutive patients with adenocarcinoma of the prostate were treated at a single institution using IMRT with curative intent.
  • In conclusion, patients treated with IMRT for prostate cancer have excellent rates of biochemical control and low rates of severe toxicity of treatment.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects


41. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R: Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol; 2008 Mar;179(3):892-5; discussion 895
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors.
  • PURPOSE: The incidence of prostate cancer has surged dramatically in recent years due to improved cancer screening and detection mechanisms.
  • There has also been significant interest specifically pertaining to the increased incidence of prostate cancer in younger males, which might be due to increased screening.
  • We analyzed our data set of incidental prostate cancer, derived from a project accruing prostate tissues for research from normal organ donors, who are a predominantly white population.
  • MATERIALS AND METHODS: Information about any prior prostate cancer screening in this cohort was not available.
  • In addition, this population had no history of intervention related to benign or malignant prostate disease.
  • RESULTS: Evaluation of serially sectioned prostate tissues revealed adenocarcinoma with or without high grade prostate intraepithelial neoplasia in 12% of cases.
  • High grade prostate intraepithelial neoplasia alone occurred in 10.6% of donors.
  • There was an age dependent increase in high grade prostate intraepithelial neoplasia starting from the 4th decade of life.
  • Prostate adenocarcinoma escalated from the 5th decade and thereafter with a 1 in 3 chance of carrying incidental cancer in the 60 to 69-year-old age group and with 46% of 70 to 81-year-old men harboring prostate cancer.
  • CONCLUSIONS: This study provides insight into the prevalence of prostate adenocarcinoma and high grade prostate intraepithelial neoplasia in the general healthy population.
  • Associated issues, such as the age at which to start screening for prostate cancer and donor transmitted malignancy, were also discussed.
  • [MeSH-major] Adenocarcinoma / epidemiology. Prostatic Intraepithelial Neoplasia / epidemiology. Prostatic Neoplasms / epidemiology


42. Stillie AL, Kron T, Fox C, Herschtal A, Haworth A, Thompson A, Owen R, Tai KH, Duchesne G, Foroudi F: Rectal filling at planning does not predict stability of the prostate gland during a course of radical radiotherapy if patients with large rectal filling are re-imaged. Clin Oncol (R Coll Radiol); 2009 Dec;21(10):760-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal filling at planning does not predict stability of the prostate gland during a course of radical radiotherapy if patients with large rectal filling are re-imaged.
  • AIMS: It has been suggested that large rectal filling is associated with an increased risk of prostate motion in radiotherapy.
  • The aim of the present study was to determine if there is a correlation between rectal distension on planning computed tomography and the intrafraction and interfraction stability of the prostate gland during a course of radical radiotherapy for prostate cancer if a protocol was used to rescan patients with excessive rectal diameter during planning.
  • MATERIALS AND METHODS: The computed tomography planning scans of 89 patients with adenocarcinoma of the prostate treated with conformal radiotherapy were reviewed.
  • All patients had three gold seed fiducial markers implanted into the prostate before planning computed tomography.
  • Rectal distension was assessed on planning computed tomography using outlines following European Organization for Research and Treatment of Cancer guidelines by measuring the rectal volume, the average cross-sectional area and the mean anterior-posterior diameter of the rectum.
  • Unifactor linear regression models showed no statistically significant relationship between intra- and interfraction prostate stability and rectal volume on planning computed tomography.
  • CONCLUSIONS: No statistically significant relationship between rectal distension on planning computed tomography and the intra- and interfraction stability of the prostate gland was identified if patients with a large rectal volume were rescanned for planning.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804961.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Suthiphongchai T, Phimsen S, Sakulkhu U, Tohtong R: PD98059-inhibited invasion of Dunning rat prostate cancer cells involves suppression of motility but not MMP-2 or uPA secretion. Oncol Rep; 2006 Jun;15(6):1605-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PD98059-inhibited invasion of Dunning rat prostate cancer cells involves suppression of motility but not MMP-2 or uPA secretion.
  • Up-regulation of extracellular-regulated kinases 1/2 (ERK1/2) has been implicated in tumor progression and metastasis in many types of cancer.
  • We have previously shown that ERK1/2 is necessary for invasiveness of Dunning rat prostatic adenocarcinoma cell lines in which levels of activated ERK1/2 correlate with the metastatic potential.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cell Movement / drug effects. Flavonoids / pharmacology. Matrix Metalloproteinase 2 / secretion. Prostatic Neoplasms / drug therapy. Urokinase-Type Plasminogen Activator / secretion

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685402.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Flavonoids; 0 / Matrix Metalloproteinase Inhibitors; 0 / Myosin Light Chains; EC 2.7.11.18 / Myosin-Light-Chain Kinase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


44. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE: Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res; 2005 Jan 1;65(1):54-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
  • Androgen is critical for prostate development, growth, and survival.
  • Therapies for advanced prostate cancer aim to block androgen receptor (AR) action.
  • We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation.
  • Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression.
  • Further investigations using both yeast and mammalian model systems revealed that multiple AR alleles are responsive to BPA, thus expanding the potential influence of xenoestrogens on prostate cancer.
  • We also show that higher concentrations of BPA block proliferation of AR-positive, androgen-dependent prostate adenocarcinoma cells (LNCaP and LAPC-4), with a more modest inhibitory effect on androgen-independent cells (22Rv-1).
  • By contrast, AR-negative prostate cancer cells failed to show growth inhibition after exposure to high BPA dose.
  • Together, these data show that BPA can serve as a potential "hormone sensitizer" of the mutant ARs present in advanced prostate adenocarcinomas, thereby possibly contributing toward therapeutic relapse in advanced prostate cancer patients and supporting the notion that nonsteroidal environmental compounds can alter the function of nuclear receptor complexes.
  • [MeSH-major] Estrogens, Non-Steroidal / pharmacology. Phenols / pharmacology. Prostatic Neoplasms / pathology. Receptors, Androgen / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665279.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / E30-ES--06096; United States / NIEHS NIH HHS / ES / ES-07250-16; United States / NCI NIH HHS / CA / R01-CA 093404-03
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Estrogens, Non-Steroidal; 0 / Phenols; 0 / Receptors, Androgen; 08J2K08A3Y / Dihydrotestosterone; EC 1.13.12.- / Luciferases; MLT3645I99 / bisphenol A
  •  go-up   go-down


45. Benedict SP, Ahuja M, Mammen KJ: Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature. Indian J Urol; 2010 Apr;26(2):287-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature.
  • Peritoneal carcinomatosis is rare in prostate cancer especially in the absence of skeletal or other visceral metastases.
  • We report a case of hormone refractory adenocarcinoma prostate presenting with only peritoneal metastases and massive malignant ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877611.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2938557
  • [Keywords] NOTNLM ; Metastasis / peritoneum / prostate cancer
  •  go-up   go-down


46. Ahmadi SA, Moinfar M, Gohari Moghaddam K, Bahadori M: Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med; 2010 Nov;13(6):498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma.
  • Although the association between vasculogenic mimicry and poor prognosis has been established in some tumors, there are only a few studies concerning prostatic carcinoma.
  • METHODS: Using a histochemical and immunohistochemical dual staining method for PAS-CD34 and special immunohistochemical staining for laminin, we studied the presence and pattern of non-endothelialized channels known as vasculogenic mimicry as well as the quantity of endothelialized vessels designated as microvessel density in usual paraffin sections of 20 low-grade and 20 high-grade prostatic adenocarcinomas by routine light microscopy.
  • CONCLUSION: Unlike other cancers and despite the results of in vitro studies on prostatic adenocarcinoma, we were not able to demonstrate a significant relationship between vasculogenic mimicry channels and histologic grading as one of the most important prognostic factors; however, this may be due to an inherent limitation of prostatic tissue imposed by abundant smooth muscle fibers stained by this method.
  • On the other hand, microvessel density scoring appears to be an important, simple, and applicable histologic tool for prostatic cancer evaluation in daily practice.
  • [MeSH-major] Adenocarcinoma / blood supply. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039005.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34
  •  go-up   go-down


47. Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, Bonnaud-Antignac A, Lisbona A, Mahé MA, Supiot S: No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):1053-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
  • PURPOSE: To determine prospectively intermediate-term toxicity and quality of life (QoL) of prostate cancer patients after intensity-modulated radiotherapy (IMRT).
  • PATIENTS AND METHODS: Fifty-five patients with localized prostate adenocarcinoma were treated by IMRT (76 Gy).
  • Patients assessed general and prostate-specific QoL before IMRT (baseline) and at 2, 6, and 18 months using European Organization for Research and Treatment of Cancer questionnaires QLQ-C30(+3) and QLQ-PR25.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Quality of Life. Radiotherapy, Intensity-Modulated / adverse effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19880259.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


48. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A; 2006 Jul 18;103(29):10991-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
  • Adenocarcinomas of the prostate can be categorized into tumor grades based on the extent to which the cancers histologically resemble normal prostate glands.
  • To identify molecular alterations underlying prostate cancer grades, we used microdissection to obtain specific cohorts of cancer cells corresponding to the most common Gleason patterns (patterns 3, 4, and 5) from 29 radical prostatectomy samples.
  • We paired each cancer sample with matched benign lumenal prostate epithelial cells and profiled transcript abundance levels by microarray analysis.
  • This model performed with 76% accuracy when applied to an independent set of 30 primary prostate carcinomas.
  • Using tissue microarrays comprising >800 prostate samples, we confirmed a significant association between high levels of monoamine oxidase A expression and poorly differentiated cancers by immunohistochemistry.
  • Furthermore, in identifying a profile of 86 genes that distinguish high- from low-grade carcinomas, we have generated a set of potential targets for modulating the development and progression of the lethal prostate cancer phenotype.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):477-8 [10757394.001]
  • [Cites] Pac Symp Biocomput. 2000;:455-66 [10902193.001]
  • [Cites] Oncogene. 2000 Aug 24;19(36):4159-69 [10962577.001]
  • [Cites] Urology. 2000 Nov 1;56(5):823-7 [11068310.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22278-86 [11294878.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5692-6 [11479199.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jan;80(1):13-23 [11867260.001]
  • [Cites] Lab Invest. 2002 May;82(5):629-37 [12004003.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):363-71 [12112525.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3206-12 [12149292.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):20-9 [12640657.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5021-30 [12902985.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3418-24 [12960131.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5376-80 [14500371.001]
  • [Cites] Eur Urol. 2003 Oct;44(4):415-22 [14499674.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4914-25 [14581366.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2560-5 [14669274.001]
  • [Cites] Neurotoxicology. 2004 Jan;25(1-2):317-24 [14697906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Prostate. 2004 May 15;59(3):337-49 [15042610.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6082-90 [15342391.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] JAMA. 1995 Aug 23-30;274(8):626-31 [7637143.001]
  • [Cites] Hum Pathol. 1996 Jul;27(7):683-7 [8698312.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):168-75 [9428494.001]
  • [Cites] Prostate. 1999 May;39(2):135-48 [10221570.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1251-6 [15502842.001]
  • [Cites] Cell. 2005 Jun 3;121(5):667-70 [15935753.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4281-92 [15806160.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):215-21; Discussion 221-3 [15992991.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53 [16145045.001]
  • [CommentIn] Eur Urol. 2007 Mar;51(3):851-2 [17421063.001]
  • (PMID = 16829574.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE5132
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK065204; United States / NCI NIH HHS / CA / P50 CA097186; United States / NCI NIH HHS / CA / P01 CA085859; United States / NCI NIH HHS / CA / P50CA97186; United States / NCI NIH HHS / CA / P01CA85859; United States / NIDDK NIH HHS / DK / DK65204
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1544162
  •  go-up   go-down


49. Mukhopadhaya A, Mendecki J, Dong X, Liu L, Kalnicki S, Garg M, Alfieri A, Guha C: Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res; 2007 Aug 15;67(16):7798-806
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate adenocarcinoma, treated with localized tumor hyperthermia (LTH), can potentially serve as a source of tumor antigen, where dying apoptotic/necrotic cells release tumor peptides slowly over time.
  • We attempted to discern whether sequential LTH and intratumoral dendritic cell and/or systemic granulocyte macrophage colony-stimulating factor (GM-CSF) would activate antitumor immune response in a syngeneic murine model of prostate cancer (RM-1).
  • These results support an in situ autovaccination strategy where systemic administration of GM-CSF and/or intratumoral injection of autologous dendritic cells, when combined with LTH, could be an effective treatment for local and systemic recurrence of prostate cancer.
  • [MeSH-major] Dendritic Cells / immunology. Hyperthermia, Induced / methods. Immunotherapy, Adoptive / methods. Prostatic Neoplasms / immunology. Prostatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699785.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


50. Akyol F, Ozyigit G, Selek U, Karabulut E: PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol; 2005 Jul;48(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
  • OBJECTIVES: To assess the factors effecting PSA bounce and to identify any possible relationship with biochemical control after 3-D conformal radiotherapy (3D-CRT) and total androgen deprivation (TAD) for prostate cancer by evaluating four previously described PSA bounce definitions.
  • METHODS: Between January 1998 and January 2001, 83 consecutive patients with clinically localized prostate cancer were treated by 3D-CRT with neoadjuvant 3 months and/or 6 months adjuvant TAD.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Androgens / therapeutic use. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods. Testosterone / blood


51. Marks RA, Zhang S, Montironi R, McCarthy RP, MacLennan GT, Lopez-Beltran A, Jiang Z, Zhou H, Zheng S, Davidson DD, Baldridge LA, Cheng L: Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate; 2008 Jun 15;68(9):919-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
  • BACKGROUND: The progression of normal prostatic epithelium to androgen-dependent cancer and, eventually, hormone-refractory prostate cancer is a complex process involving many different growth regulatory signals.
  • Activation of epidermal growth factor receptor (EGFR) has been implicated in prostate cancer cell growth.
  • METHODS: This study was undertaken to investigate both amplification of EGFR gene by fluorescence in situ hybridization (FISH) and over-expression of EGFR by immunohistochemical staining in prostate tissue from 71 patients treated by hormonal therapy.
  • CONCLUSIONS: We found that EGFR gene expression was detectable in 35% of this large series of hormone-treated prostate cancer, and that EGFR protein is frequently expressed in tissue from these patients.
  • EGFR over-expression may serve as a reasonable target for therapeutic intervention in this otherwise difficult to treat subset of prostate cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Androgen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / enzymology. Prostatic Neoplasms / enzymology. Receptor, Epidermal Growth Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409189.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


52. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):217-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
  • Here, we establish the clinical significance of matriptase and its inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), during the progression of human prostate cancer (CaP).
  • METHODS: The expression patterns of matriptase and HAI-1 were determined in primary cultures of normal human prostate epithelial (NHPE) cells, human CaP cells LNCaP, DU-145, CWR22Rnu1, and PC-3, and in tissue samples of 172 patients with normal prostate, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma of different tumor grades.
  • Tissue samples of normal prostate exhibited a high constitutive protein level of HAI-1 compared with BPH and low-grade cancer with a progressive loss with increasing tumor grade.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Membrane Glycoproteins / metabolism. Neoplasm Staging / methods. Prostatic Neoplasms / pathology. Serine Endopeptidases / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492908.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / RNA, Messenger; 0 / SPINT1 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  •  go-up   go-down


53. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • INTRODUCTION: Prostate cancer has a high tendency to spread to bone.
  • Few patients with prostate cancer present initially with symptomatic metastatic lung lesions and lymphadenopathy without any other concomitant distant dissemination.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


54. Yagihashi Y, Okinami T, Fukuzawa S, Kuriki K: [Pericardial effusion due to metastatic prostate cancer: a case report]. Hinyokika Kiyo; 2008 May;54(5):369-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pericardial effusion due to metastatic prostate cancer: a case report].
  • We describe a patient whose complaints were related to pericardial effusion due to prostatic carcinoma.
  • Cytologic study suggested metastatic adenocarcinoma or malignant mesothelioma.
  • At autopsy, the major finding was poorly differentiated adenocarcinoma of the prostate with metastases to the mediastinum.
  • [MeSH-major] Adenocarcinoma / pathology. Mediastinal Neoplasms / secondary. Pericardial Effusion / etiology. Prostatic Neoplasms / pathology


55. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M: Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol; 2007 Jun;4(6):321-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) is the most likely precursor of prostatic adenocarcinoma according to virtually all available evidence.
  • This lesion is characterized by cellular proliferations within pre-existing ducts and acini, with nuclear and nucleolar enlargements similar to those seen in prostate cancer, although unlike cancer HGPIN retains a basal-cell layer.
  • The recognition of HGPIN is clinically important because of the strong association between this disease and prostatic carcinoma.
  • The predictive value for cancer of an initial diagnosis of HGPIN on needle biopsy has substantially declined, with values falling from 36% to 21%.
  • Other possible findings in the prostate might indicate premalignant disease (low-grade prostatic intraepithelial neoplasia, atrophy, malignancy-associated changes, and atypical adenomatous hyperplasia or adenosis), but the data for these premalignant diseases are much less convincing than those for HGPIN.
  • [MeSH-major] Precancerous Conditions. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biopsy, Needle. Humans. Male. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551536.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


56. Larson GP, Ding Y, Cheng LS, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, MacDonald D, Archambeau J, Slater J, Neuberg D, Daly MB, Angel I, Benson AB 3rd, Smith K, Kirkwood JM, O'Dwyer PJ, Raskay B, Sutphen R, Drew R, Stewart JA, Werndli J, Johnson D, Ruckdeschel JC, Elston RC, Krontiris TG: Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Res; 2005 Feb 1;65(3):805-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT.
  • We conducted linkage analysis of 80 candidate genes in 201 brother pairs affected with prostatic adenocarcinoma.
  • Our results strongly suggest involvement of germline variations of FHIT in prostate cancer risk.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenocarcinoma / genetics. Chromosomes, Human, Pair 3 / genetics. Genetic Linkage / genetics. Neoplasm Proteins / genetics. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705877.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG 15720; United States / NIGMS NIH HHS / GM / GM 28356; United States / NCRR NIH HHS / RR / RR 03655
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


57. Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE: A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene; 2005 Jan 13;24(3):431-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regulation of nuclear receptor activity is the focus of numerous ongoing studies to develop novel therapies for the treatment of hormone-related cancer.
  • Strikingly, overexpression of this repressor region attenuates cell cycle progression in prostatic adenocarcinoma cells.
  • In addition, our data suggest that properties of the cyclin D1 central domain could be exploited to develop novel prostate cancer therapeutics.
  • [MeSH-minor] Amino Acid Sequence. Animals. COS Cells. Cercopithecus aethiops. Flow Cytometry. Genes, Reporter. Humans. Male. Models, Molecular. Molecular Sequence Data. Plasmids. Prostatic Neoplasms. Protein Conformation. Sequence Deletion. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558026.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA93237; United States / NICHD NIH HHS / HD / HDO7200-15; United States / NIEHS NIH HHS / ES / P30-ES06096; United States / NCI NIH HHS / CA / R01 CA099996
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Androgen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


58. Masue N, Hasegawa Y: [Giant prostate carcinoma treated effectively with endocrine therapy: case report]. Hinyokika Kiyo; 2007 Feb;53(2):133-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
  • Computed tomography (CT) and magnetic resonance imaging revealed a giant prostate tumor.
  • The histologic diagnosis was moderately differentiated adenocarcinoma of prostate.
  • Four months later, CT showed that the tumor had decreased markedly in size, and the serum prostate specific antigen level was within normal range.
  • Hormone refractory prostate cancer was not found 1 year after the start of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlormadinone Acetate / therapeutic use. Goserelin / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged, 80 and over. Anilides / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Humans. Magnetic Resonance Imaging. Male. Naphthalenes / administration & dosage. Nitriles. Piperazines / administration & dosage. Prostate-Specific Antigen / blood. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Naphthalenes; 0 / Nitriles; 0 / Piperazines; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; 0SY050L61N / Chlormadinone Acetate; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; R9PHW59SFN / naftopidil
  •  go-up   go-down


59. Gómez E, Contreras-Ordoñez G, Ramírez-Apan T: Synthesis, characterization and in vitro cytotoxicity of pentacoordinated Tin(IV) complexes derived from aminoalcohols. Chem Pharm Bull (Tokyo); 2006 Jan;54(1):54-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All compounds were evaluated for in vitro cytotoxic activities against five human tumor cell lines, U251 (human glioblastoma), PC-3 (human prostatic adenocarcinoma), K-562 (human chronic myelogenous leukemia), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394549.001).
  • [ISSN] 0009-2363
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Alcohols; 0 / Antineoplastic Agents; 0 / Indicators and Reagents; 0 / Ligands; 0 / Organotin Compounds
  •  go-up   go-down


60. Kim SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee SH: Immunohistochemical analysis of Fas and FLIP in prostate cancers. APMIS; 2009 Jan;117(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of Fas and FLIP in prostate cancers.
  • Fas-mediated apoptosis is considered a principal pathway for apoptosis induction in normal and cancer cells.
  • Expression of Fas has been reported in prostate tissues several times, but the data were not consistent.
  • Expression of FLICE-like inhibitory protein (FLIP), an inhibitor of Fas-mediated apoptosis, has not been studied by immunohistochemistry in prostate tissues.
  • The aim of this study is to explore whether alterations of Fas and FLIP expression occur in prostate cancer tissues.
  • We analyzed the expression of Fas and FLIP in 107 prostate adenocarcinoma tissues by immunohistochemistry using a tissue microarray approach.
  • Prostate intraepithelial neoplasm also showed a strong Fas immunoreactivity.
  • The decreased expression of Fas in a large fraction of prostate cancers compared with their normal cells suggested that loss of Fas expression might play a role in tumorigenesis in some prostate cancers possibly by inhibiting apoptosis mediated by Fas.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD95 / metabolism. CASP8 and FADD-Like Apoptosis Regulating Protein / metabolism. Prostate / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19161534.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein
  •  go-up   go-down


61. Agarwal MM, Mandal AK, Khandelwal N, Singh SK: Need for measurement of bone mineral density in patients of prostate cancer before and after orchidectomy: role of quantitative computer tomography. J Assoc Physicians India; 2007 Jul;55:486-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Need for measurement of bone mineral density in patients of prostate cancer before and after orchidectomy: role of quantitative computer tomography.
  • BACKGROUND: Androgen deprivation therapy is the first-line systemic treatment of prostate cancer, orchidectomy remaining the most common mode in view of cost-effectiveness and better compliance.
  • MATERIAL AND METHODS: Fifty five patients of adenocarcinoma prostate opting for orchidectomy were prospectively studied.
  • CONCLUSIONS: Osteoporosis is common in hormone-naive population affected by prostate cancer and orchidectomy leads to accelerated exacerbation of this bone loss.
  • [MeSH-major] Absorptiometry, Photon. Orchiectomy / adverse effects. Osteoporosis / radiography. Prostatic Neoplasms / surgery. Tomography, X-Ray Computed


62. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE: Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res; 2007 Jul 1;67(13):6192-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
  • The retinoblastoma tumor suppressor protein (RB), a critical mediator of cell cycle progression, is functionally inactivated in the majority of human cancers, including prostatic adenocarcinoma.
  • The importance of RB tumor suppressor function in this disease is evident because 25% to 50% of prostatic adenocarcinomas harbor aberrations in RB pathway.
  • These data indicate that RB deficiency can facilitate bypass of first-line hormonal therapies used to treat prostate cancer.
  • In this context, RB-deficient prostate cancer cells showed enhanced susceptibility to cell death induced by only a selected subset of cytotoxic agents (antimicrotubule agents and a topoisomerase inhibitor).
  • Combined, these data indicate that RB depletion dramatically alters the cellular response to therapeutic intervention in prostate cancer cells and suggest that RB status could potentially be developed as a marker for effectively directing therapy.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Feb 14;21(8):1196-207 [11850839.001]
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):550-4 [15577431.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26321-6 [12015321.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):141-51 [15802019.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10243-54 [16288012.001]
  • [Cites] Cell. 2006 Feb 10;124(3):615-29 [16469706.001]
  • [Cites] Breast Cancer Res Treat. 2006 Apr;96(3):279-92 [16328721.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7783-92 [16885382.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Oncogene. 2006 Aug 28;25(38):5220-7 [16936740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15540-5 [17030815.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):17-26 [17007996.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11897-906 [17178887.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11998-2008 [17178899.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):218-28 [17160137.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):51-60 [17218635.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):8085-93 [15585644.001]
  • [Cites] Cell Growth Differ. 2000 Jul;11(7):361-72 [10939590.001]
  • [Cites] Lab Invest. 2000 Sep;80(9):1455-64 [11005213.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7751-63 [11003670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10820-5 [10995475.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9273-8 [11108719.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5038-44 [11431338.001]
  • [Cites] Prostate. 2001 Sep 15;48(4):254-64 [11536305.001]
  • [Cites] Cancer Lett. 2002 Nov 28;185(2):191-9 [12169393.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6587-97 [12438254.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):223-8 [12853964.001]
  • [Cites] J Cell Sci. 2004 May 1;117(Pt 11):2173-81 [15126619.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29278-85 [15105433.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6018-25 [15342382.001]
  • [Cites] Prostate. 2004 Dec 1;61(4):332-53 [15389811.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7762-6 [2217208.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Feb;15(2):108-14 [8834174.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4511-6 [9377562.001]
  • [Cites] Prostate. 1998 Feb 1;34(2):145-51 [9465946.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20213-22 [9685369.001]
  • [Cites] Int J Oncol. 1999 Jan;14(1):5-14 [9863003.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3365-83 [9916999.001]
  • [Cites] Prostate. 1999 Apr 1;39(1):47-53 [10221266.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • (PMID = 17616676.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121402-03; United States / NCI NIH HHS / CA / R21 CA121402; United States / NCI NIH HHS / CA / CA099996; United States / NCI NIH HHS / CA / CA116777; United States / NCI NIH HHS / CA / T32 CA117846; United States / NCI NIH HHS / CA / R01 CA106471; United States / NCI NIH HHS / CA / R21 CA121402-03; United States / NCI NIH HHS / CA / R01 CA099996; United States / NCI NIH HHS / CA / R01 CA116777
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Receptors, Androgen; 0 / Retinoblastoma Protein; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS206977; NLM/ PMC4133940
  •  go-up   go-down


63. Scaggiante B, Bonin S, Cristiano L, Siracusano S, Stanta G, Dapas B, Giansante C, Fiotti N, Grassi G: Prostate-tumor-inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma infection. Cancer Invest; 2008 Oct;26(8):800-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-tumor-inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma infection.
  • The potential role of PTI-1, in the natural story of prostate adenocarcinoma remains to be fully determined.
  • PTI-1 expression was evaluated in human prostate cancer cell lines and in paraffin-embedded archive tissues.
  • The lack of PTI-1 expression was also confirmed in fixed and paraffin-embedded human cancer prostate biopsies.
  • The overall data indicate that, in prostate tumor cell lines, PTI-1 presence parallels Mycoplasma infection suggesting that PTI-1 might not necessarily play a major role in the onset of prostate tumorigenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Mycoplasma hyorhinis / genetics. Neoplasm Proteins / analysis. Peptide Elongation Factor 1 / analysis. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853312.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EEF1A1 protein, human; 0 / Neoplasm Proteins; 0 / Peptide Elongation Factor 1; 0 / RNA, Bacterial; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


64. Stewart J, Fleshner N, Cole H, Sweet J: Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol; 2007 Jul;60(7):773-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
  • BACKGROUND: Current ancillary markers for diagnosis in prostate biopsies include p63 and alpha-methylacyl-CoA racemase (AMACR).
  • Annexin II (ANXII), a calcium and phospholipid binding protein, is lost in prostate cancer.
  • Staining was evaluated in benign and atrophic glands, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma.
  • ANXII loss in prostate cancer was found in 282/320 cores (88%) and correlated with positive AMACR expression (272/320 cores, 85%), which was not statistically significant.
  • CONCLUSIONS: Immunohistochemical staining for ANXII is a consistent and reliable marker of prostatic neoplasia.
  • The findings of this study suggest the potential utility of ANXII as a diagnostic aid in prostate cancer histopathology.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A2 / metabolism. Biomarkers, Tumor / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. DNA-Binding Proteins / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / metabolism. Organ Size. Prostate / pathology. Prostatectomy. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Intraepithelial Neoplasia / surgery. Racemases and Epimerases / metabolism. Trans-Activators / metabolism. Transcription Factors. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):916-20 [14713853.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):13-9 [16330937.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):852-63 [14991775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3450-5 [14985510.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):328-48 [14976539.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Mol Cancer. 2003 Oct 8;2:34 [14613585.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):368-74 [15338305.001]
  • [Cites] J Biol Chem. 1986 Jun 5;261(16):7247-52 [2940239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4258-62 [3012561.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):3216-23 [2160596.001]
  • [Cites] Differentiation. 1993 Mar;52(3):229-37 [8387039.001]
  • [Cites] Carcinogenesis. 1993 Dec;14(12):2575-9 [8269629.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):313-23 [8020470.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14399-404 [7782301.001]
  • [Cites] Oncol Res. 1994;6(12):561-7 [7787249.001]
  • [Cites] Prostate. 1997 Sep 15;33(1):32-7 [9294624.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):215-30 [10708859.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6331-4 [11522620.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1475-85 [12629510.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):772-8 [12766580.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):449-61 [15928709.001]
  • [Cites] Histol Histopathol. 2005 Jul;20(3):673-80 [15944914.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1219-23 [16287434.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):363-74 [16300650.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):307-15 [14599294.001]
  • (PMID = 16916997.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A2; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC1995785
  •  go-up   go-down


66. Martino P, Martino D, Palazzo S, Altomare DF, Garofalo L, Battaglia M, Selvaggi FP: Incidental discovery of ano-rectal disease during transrectal ultrasound performed for prostatic disease. Arch Ital Urol Androl; 2005 Mar;77(1):37-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental discovery of ano-rectal disease during transrectal ultrasound performed for prostatic disease.
  • Transrectal ultrasound (US) has long been a routine investigation for the study of various diseases of the prostate.
  • In 34 patients (7%) a malignant tumor was found (infiltration of the anterior rectal wall by a prostatic adenocarcinoma in 13, and a primitive adenocarcinoma of rectal origin in the remaining 21).
  • It can be concluded that transrectal US does not permit a certain diagnosis of the nature of rectal disease, but does raise a diagnostic suspicion that can orient the surgeon to schedule more invasive diagnostic investigations.

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906788.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


67. Metzdorf MM, Schmidt JD: Isolated prostate cancer recurrence presenting as pelvic mass nine years after radical retropubic prostatectomy. Urology; 2007 Nov;70(5):1007.e17-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated prostate cancer recurrence presenting as pelvic mass nine years after radical retropubic prostatectomy.
  • Pelvic seeding from radical retropubic prostatectomy for adenocarcinoma of the prostate is uncommon.
  • We describe a patient who presented with a prostate-specific antigen recurrence and was found to have a solitary metastasis adjacent to his pubic bone 9 years after radical prostatectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Pelvic Neoplasms / diagnosis. Prostatectomy. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068468.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Guzman Martinez-Valls PL, Rodríguez Tardido A, Honrubia Vilchez B, Izquierdo Morejon E, Pietricica BN, Montoya Chinchilla R, Rosino Sanchez A, Hita Villaplana G, Romero Hoyuela A, Miñana Lopez B: [Frontal mass simulating lipoma as a clinical presentation of prostatic adenocarcinoma]. Arch Esp Urol; 2009 Jan-Feb;62(1):66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frontal mass simulating lipoma as a clinical presentation of prostatic adenocarcinoma].
  • [Transliterated title] Bultoma frontal simulando lipoma como manifestación de adenocarcinoma de próstata.
  • OBJECTIVE: To report one case of metastatic prostatic carcinoma with a gaudy presentation as a lump which resulted to be a cutaneous metastasis.
  • METHODS: We describe the debut in a patient, who thanks to the pathologic analysis of a lesion mimicking a lipoma, which was reported as adenocarcinoma, was worked up for prostatic adenocarcinoma and diagnosis was reached.
  • We performed a bibliographic review using an electronic bibliographic search in PubMed (MEDLINE) using the terms "Prostatic Neoplasm" (MesH) AND "Neoplasm Metastasis" (MesH) AND "cutaneous" (free text).
  • Cutaneous metastasis of prostatic origin appear in less than 0.3% of the cases, because bone, lymph node, and visceral disease are more frequent.
  • CONCLUSIONS: Cutaneous metastases of prostatic adenocarcinoma are very rare, but even rarer is it being the debut of the disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Lipoma / diagnosis. Prostatic Neoplasms / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male


69. Matsuoka Y, Arai G, Okada Y, Aida J: Prostate cancer-producing granulocyte colony-stimulating factor. Urol Int; 2009;82(1):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer-producing granulocyte colony-stimulating factor.
  • An 86-year-old man with a serum prostate-specific antigen level of 93.33 ng/ml was diagnosed as having cT3aN0M0 prostatic adenocarcinoma of Gleason score 9.
  • Although the serum prostate-specific antigen responded well to combined androgen blockade, the cancer spread and lead to death 6 months after diagnosis.
  • The patient had leukocytosis during the clinical course with no sign of localized infection, especially after manipulation of the prostate.
  • To our knowledge, this is the first case of prostate cancer with G-CSF production, which was confirmed immunohistochemically.
  • [MeSH-major] Adenocarcinoma / metabolism. Granulocyte Colony-Stimulating Factor / blood. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Aged, 80 and over. Androgen Antagonists / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Immunohistochemistry. Macrophage Colony-Stimulating Factor / blood. Male. Neoplasm Metastasis. Neoplasm Staging. Prostate-Specific Antigen / blood. Treatment Failure

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19172109.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 81627-83-0 / Macrophage Colony-Stimulating Factor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


70. Bruyère F, Faivre d'Arcier B, Haringanji DC, Boutin JM, Haillot O, Lanson Y: Effect of patient position on pain experienced during prostate biopsy. Urol Int; 2007;78(4):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of patient position on pain experienced during prostate biopsy.
  • OBJECTIVES: To compare pain during prostate biopsy performed in two different positions.
  • The men with prostate adenocarcinoma tolerated biopsies better than the others.
  • CONCLUSION: Our results suggest that the lithotomy position induced less pain and less post-biopsy hematuria than did the lateral position during prostate biopsy.
  • Men with prostate adenocarcinoma tolerated the procedures better.
  • [MeSH-major] Pain. Posture. Prostate / pathology

  • MedlinePlus Health Information. consumer health - Guide to Good Posture.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495495.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  •  go-up   go-down


71. de Melo-Júnior MR, Araújo-Filho JL, Lins CA, de Pontes-Filho NT, de Carvalho LB Jr: Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis. Appl Biochem Biotechnol; 2010 Apr;160(8):2198-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis.
  • This work aimed to immobilize the antibody anti-galectin-3 onto polysiloxane-polyvinyl alcohol (POS-PVA) support, to evaluate its capacity to capture the serum antigen galectin-3 and to quantify by ELISA the antigen levels in sera from patients with prostatic adenocarcinoma (PA) and benign prostatic hyperplasia (BPH) and healthy individuals.
  • Also, for comparative effect, the galectin-3 expression in the prostate tissue through immunohistochemistry was evaluated.
  • Galectin-3 immunohistochemically showed a significant increase and reduction of the cytoplasmatic protein expression in BPH and PA, respectively, compared with the normal prostate.
  • [MeSH-major] Galectin 3. Polyvinyl Alcohol / chemistry. Prostatic Hyperplasia. Prostatic Neoplasms. Siloxanes / chemistry
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Enzyme-Linked Immunosorbent Assay / methods. Humans. Male. Middle Aged. Prostate / cytology. Prostate / metabolism. Prostate / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. POLYVINYL ALCOHOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728168.001).
  • [ISSN] 1559-0291
  • [Journal-full-title] Applied biochemistry and biotechnology
  • [ISO-abbreviation] Appl. Biochem. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galectin 3; 0 / Siloxanes; 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down


72. Uluocak N, Parlaktas BS, Deniz FE, Erdemir F, Koseoglu RD, Gedar MO: Orbital metastasis of prostate cancer: a case report. Kaohsiung J Med Sci; 2007 Apr;23(4):199-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis of prostate cancer: a case report.
  • We report a case with metastatic orbital cancer secondary to prostatic adenocarcinoma.
  • However, the disease subsequently progressed and the patient died 12 months after diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Orbital Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395569.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


73. Kiuchi H, Ujike T, Miyake O, Namba Y: [A case of further significant anastomotic rupture after gentle traction of urethral catheter for minimal anastomotic leakage after radical retropubic prostatectomy]. Hinyokika Kiyo; 2006 Feb;52(2):151-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old man with clinical stage T1c adenocarcinoma of the prostate underwent radical retropubic prostatectomy.
  • [MeSH-major] Extravasation of Diagnostic and Therapeutic Materials / diagnosis. Prostatectomy / adverse effects. Urethra / surgery. Urinary Bladder / surgery. Urinary Catheterization
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Humans. Magnetic Resonance Imaging. Male. Postoperative Complications. Prostatic Neoplasms / surgery. Rupture. Traction / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541772.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Neuzillet Y, Méjean A, Lebret T: [Oncogeriatric evaluation for elderly patients suffering from metastatic urologic malignancies]. Prog Urol; 2008 Nov;18 Suppl 7:S415-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evaluation oncogériatrique du sujet âgé ayant un cancer urologique métastatique.
  • The elderly are often the population affected by urologic cancer, especially prostate adenocarcinoma and urothelial tumors.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070825.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Sun Y, Eichelbaum EJ, Skelton WP 4th, Lenz A, Wang H, Vesely DL: Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res; 2009 Apr;29(4):971-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.
  • BACKGROUND: Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas.
  • MATERIALS AND METHODS: The effects of vessel dilator, kaliuretic peptide and cyclic GMP on Ras were examined in human prostate adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Atrial Natriuretic Factor / pharmacology. Prostatic Neoplasms / drug therapy. Protein Precursors / pharmacology. ras Proteins / antagonists & inhibitors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414334.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Protein Precursors; 0 / atrial natriuretic factor precursor (79-98); 0 / atrial natriuretic factor prohormone (31-67); 146-91-8 / Guanosine Diphosphate; 37589-80-3 / Guanosine 5'-O-(3-Thiotriphosphate); 85637-73-6 / Atrial Natriuretic Factor; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; EC 3.6.5.2 / ras Proteins; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


76. Sun Y, Eichelbaum EJ, Wang H, Vesely DL: Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells. Anticancer Res; 2006 Sep-Oct;26(5A):3217-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells.
  • BACKGROUND: Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas.
  • MATERIALS AND METHODS: Vessel dilator, kaliuretic peptide and cyclic GMP's effects on ERK 1/2 kinase were examined in human prostate adenocarcinoma cells.
  • [MeSH-major] Atrial Natriuretic Factor / pharmacology. Enzyme Activation / drug effects. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Prostatic Neoplasms / drug therapy. Protein Precursors / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Cyclic GMP / pharmacology. Humans. Immunoblotting. Male. Natriuresis. Peptide Fragments / pharmacology. Phosphorylation / drug effects. Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094432.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Protein Precursors; 0 / atrial natriuretic factor precursor (79-98); 0 / atrial natriuretic factor prohormone (31-67); 85637-73-6 / Atrial Natriuretic Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


77. Sánchez C, Clementi M, Benitez D, Contreras H, Huidobro C, Castellón E: Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma. Prostate; 2005 Nov 1;65(3):195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.
  • BACKGROUND: GnRH analogs have antiproliferative and/or apoptotic effects on prostate cancer cells.
  • Also, neurotrophin receptors TrkA and p75 have been reported in normal prostate suggesting a role in the gland growth control.
  • In prostate cancer, TrkA receptors seem to be overexpressed and p75 receptors show a decreased expression.
  • In the present study we investigate the effects of GnRH analogs (leuprolide and cetrorelix) on the expression of TrkA and p75 neurotrophin receptors in primary cultures of human prostate cancer cells.
  • METHODS: Tissue was obtained from radical prostatectomies due to prostate adenocarcinoma.
  • Considering that TrkA receptor is related with proliferation and p75 with apoptosis, we suggest that our findings may explain, in part, the effect of GnRH analogs on prostate cancer growth.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / pharmacology. Gonadotropin-Releasing Hormone / analogs & derivatives. Leuprolide / pharmacology. Prostatic Neoplasms / drug therapy. Receptor, trkA / biosynthesis. Receptors, Nerve Growth Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CETRORELIX .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15948150.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Formazans; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Tetrazolium Salts; 23305-68-2 / MTT formazan; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 2.7.10.1 / Receptor, trkA; EFY6W0M8TG / Leuprolide; OON1HFZ4BA / cetrorelix
  •  go-up   go-down


78. Noel EE, Ragavan N, Walsh MJ, James SY, Matanhelia SS, Nicholson CM, Lu YJ, Martin FL: Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland. Prostate Cancer Prostatic Dis; 2008;11(2):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland.
  • Gene expression profiles may lend insight into whether prostate adenocarcinoma (CaP) predominantly occurs in the peripheral zone (PZ) compared to the transition zone (TZ).
  • From human prostates, tissue sets consisting of PZ and TZ were isolated to investigate whether there is a differential level of gene expression between these two regions of this gland.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646851.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


79. Sagnak L, Topaloglu H, Gucuk O, Han U, Ersoy H: Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma. Pathol Oncol Res; 2008 Dec;14(4):493-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Papillary / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Cell Differentiation. Humans. Incidental Findings. Lymph Nodes / pathology. Male. Middle Aged. Neck / pathology. Nitriles / therapeutic use. Orchiectomy. Prostate-Specific Antigen / blood. Prostatectomy. Thyroidectomy. Tosyl Compounds / therapeutic use. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1992 Mar;23(3):287-96 [1313390.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):570-3 [15717656.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Endocr J. 2004 Aug;51(4):445-8 [15351802.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):149-61 [10839615.001]
  • [Cites] Arch Esp Urol. 2003 Sep;56(7):859-61 [14595895.001]
  • [Cites] Am J Otolaryngol. 2001 Nov-Dec;22(6):420-3 [11713729.001]
  • [Cites] Chang Gung Med J. 2004 Nov;27(11):840-4 [15796261.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):357-61 [8674017.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(3):293-5; discussion 295 [15897914.001]
  • [Cites] Pathol Int. 2004 Dec;54(12):918-23 [15598314.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2001 Sep-Oct;56(5):153-8 [11781596.001]
  • (PMID = 18386164.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


80. Kunju LP, Mehra R, Snyder M, Shah RB: Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol; 2006 May;125(5):675-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
  • An optimal immunohistochemical panel to distinguish poorly differentiated prostate (PCa) from urothelial (UCa) carcinoma was selected from a panel consisting of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), high-molecular-weight cytokeratin (HMWCK), clone 34betaE12, cytokeratin (CK) 7, CK20, p63, and alpha-methylacyl-coenzyme A racemase.
  • Negative PSA with positive HMWCK and/or p63 establishes a diagnosis of UCa.
  • [MeSH-major] Adenocarcinoma / diagnosis. Immunohistochemistry / methods. Keratins / analysis. Membrane Proteins / analysis. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Molecular Weight. Pilot Projects. Urothelium / chemistry. Urothelium / pathology


81. Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T: Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis; 2008 Jun;29(6):1134-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells.
  • Prostate cancers generally acquire an androgen-independent growth capacity with progression, resulting in resistance to antiandrogen therapy.
  • Therefore, identification of the genes regulated through this process may be important for understanding the mechanisms of prostate carcinogenesis.
  • We here utilized androgen-dependent/independent transplantable tumors, newly established with the 'transgenic rat adenocarcinoma in prostate' (TRAP) model, to analyze their gene expression using microarrays.
  • Among the overexpressed genes in androgen-independent prostate cancers compared with the androgen-dependent tumors, glutathione S-transferase pi (GST-pi) was included.
  • In line with this, human prostate cancer cell lines PC3 and DU145 (androgen independent) had higher expression of GST-pi compared with LNCaP (androgen dependent) as determined by semiquantitative reverse transcription-polymerase chain reaction analysis.
  • To investigate the roles of GST-pi expression in androgen-independent human prostate cancers, GST-pi was knocked down by a small interfering RNA (siRNA), resulting in significant decrease of the proliferation rate in the androgen-independent PC3 cell line.
  • These findings suggest that GST-pi might play important roles in proliferation of androgen-independent human prostate cancer cells.
  • [MeSH-major] Cell Proliferation. Glutathione S-Transferase pi / metabolism. Prostatic Neoplasms / metabolism


82. Tsujino K, Sasada S, Kawahara K, Terada H, Komori C, Suzuki H, Okamoto N, Kobayashi M, Hirashima T, Matsui K, Kawase I: [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy]. Nihon Kokyuki Gakkai Zasshi; 2007 Aug;45(8):648-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy].
  • We report a 70-year-old man with prostatic carcinoma presenting as supraclaviculer and mediastinal lymphadenopathy.
  • He had no urinary tract symptoms, and computed tomography and FDG-PET showed no abnormality in the prostate or pelvic lymph nodes.
  • Metastatic prostatic adenocarcinoma was finally diagnosed from the results of immunohistochemical staining for PSA of a biopsy specimen of the mediastinal lymph node, and he was treated by hormonal therapy.
  • There are fears that some other similar cases might be treated with chemotherapy as lung cancer without immunohistochemical staining.
  • Prostatic carcinoma should always be considered in the differential diagnosis of elderly men with supraclaviculer or mediastinal lymph node metastases, since appropriate treatment will lead to a prolonged survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymph Nodes / pathology. Lymphatic Diseases / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Lymphatic Metastasis. Male. Mediastinum. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763696.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


83. Stockdale AD, Vakkalanka BK, Fahmy A, Desai K, Blacklock AR: Management of biochemical failure following radical prostatectomy: salvage radiotherapy - a case series. Prostate Cancer Prostatic Dis; 2007;10(2):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective analysis of the outcome of radical prostatectomy (RP) for prostate cancer in a single centre and assessment of the role of salvage radiotherapy (RT) for patients with biochemical relapse.
  • Hundred and thirty-seven patients underwent RP for adenocarcinoma of the prostate in our centre between December 1994 and June 2003.
  • Fifty-four of these patients developed a biochemical relapse prostate-specific antigen (PSA > or = 0.2 ng/ml).
  • [MeSH-major] Adenocarcinoma / surgery. Prostatic Neoplasms / surgery. Salvage Therapy / methods
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatectomy. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310262.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


84. Venkitaraman R, Thomas K, Grace P, Dearnaley D, Horwich A, Huddart R, Parker CC: Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. Int J Biol Markers; 2008 Jul-Sep;23(3):192-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population.
  • AIM: To determine whether urinary concentrations of phytoestrogens are associated with the rate of disease progression in men with untreated, localised prostate cancer.
  • PATIENTS AND METHODS: Patients with untreated, localised prostatic adenocarcinoma on a prospective clinical study of active surveillance had urine samples collected at baseline.
  • Patients underwent monitoring with serial PSA levels and repeat octant prostate biopsies.
  • CONCLUSION: These data do not support the hypothesis that phytoestrogens prevent disease progression in men with localised prostate cancer.
  • [MeSH-major] Phytoestrogens / metabolism. Phytoestrogens / urine. Prostatic Neoplasms / urine
  • [MeSH-minor] Aged. Biopsy. Dietary Supplements. Disease Progression. Humans. Male. Middle Aged. Prospective Studies. Prostate / pathology. Prostate-Specific Antigen / biosynthesis. Treatment Outcome. United Kingdom

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949747.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10588; United Kingdom / Medical Research Council / / G0501019; United Kingdom / Cancer Research UK / / C46/A2131
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phytoestrogens; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


85. Vijan SS, Wall JC, Greenlee SM, Farley DR: Consequences of endoscopic inguinal hernioplasty with mesh on subsequent open radical prostatectomy. Hernia; 2008 Aug;12(4):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case controls (n = 26) were matched for age, type of operation, year of surgery and pathologic stage of prostatic adenocarcinoma.
  • CONCLUSIONS: Prior TEP/TAPP did not increase the morbidity or mortality of subsequent prostate surgery.
  • While endoscopic hernia repair remains an excellent option to fix unilateral, bilateral, and recurrent herniae, consideration of future prostate surgery is important.
  • Inserting less "inflammatory" mesh or using an open, anterior approach may be prudent in some men at high risk for needing subsequent prostate surgery.
  • [MeSH-major] Endoscopy / methods. Hernia, Inguinal / surgery. Prostatectomy / adverse effects. Prostatic Neoplasms / surgery. Prosthesis Implantation / instrumentation. Reconstructive Surgical Procedures / methods. Surgical Mesh
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome


86. Lau SK, Chu PG: Prostatic tissue ectopia within the seminal vesicle: a potential source of confusion with seminal vesicle involvement by prostatic adenocarcinoma. Virchows Arch; 2006 Nov;449(5):600-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic tissue ectopia within the seminal vesicle: a potential source of confusion with seminal vesicle involvement by prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Choristoma / pathology. Genital Diseases, Male / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Seminal Vesicles / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2005 Dec;12(12):1066-8 [16409614.001]
  • [Cites] J Ultrasound Med. 1994 Jul;13(7):578-80 [7933023.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):e60-2 [15043474.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):209-15 [16434895.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):2126-9 [9817337.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):194-7 [16454561.001]
  • [Cites] J Urol. 1971 Jan;105(1):97-104 [5100878.001]
  • [Cites] Urology. 1996 Sep;48(3):490-3 [8804510.001]
  • [Cites] Prostate. 2005 Feb 15;62(3):260-6 [15389778.001]
  • (PMID = 17016717.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


87. Grenader T, Shavit L: Synchronous male breast cancer and carcinoma of prostate in 90-year-old male, presented with spinal cord compression and multiple spine lytic lesions. Breast J; 2007 Jul-Aug;13(4):410-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous male breast cancer and carcinoma of prostate in 90-year-old male, presented with spinal cord compression and multiple spine lytic lesions.
  • Male breast cancer and prostate cancer are similar in many ways, including the potential role of steroid hormones in their pathogenesis.
  • We describe a 90-year-old male patient, who came with synchronous male breast cancer and carcinoma of the prostate.
  • A histological examination of a specimen from a lytic lesion of the spine was consistent with metastatic breast cancer and a needle biopsy of the prostate showed adenocarcinoma, Gleason score 3 + 4.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms, Male / pathology. Neoplasms, Multiple Primary. Prostatic Neoplasms / pathology. Soft Tissue Neoplasms / complications. Soft Tissue Neoplasms / secondary. Spinal Cord Compression / etiology. Spinal Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Palliative Care. Paraparesis / etiology. Prostate-Specific Antigen / blood. Spinal Canal / pathology


88. Voeghtly LM, Thøgersen IB, Valnickova Z, Sanggaard KW, Chu CT, Oury TD, Enghild JJ: Potential clinical importance of the activation peptide of prostate-specific antigen. Int J Clin Exp Pathol; 2009;2(6):588-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential clinical importance of the activation peptide of prostate-specific antigen.
  • Prostate cancer is the second leading cause of cancer death in men.
  • Prostate specific antigen (PSA) is currently the best marker available for screening and monitoring disease recurrence, but its use has limitations.
  • This study investigates the biosynthesis, secretion and activation of PSA in a prostate adenocarcinoma cell line.
  • This rapid clearance likely interferes with detection of PSA in the early stages of prostate cancer.
  • We found that APLILSR is filtered from the bloodstream by the kidney, and is detectable in the urine of patients with prostate cancer, but not controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 1976 Jan;79(1):233-6 [939761.001]
  • [Cites] J Urol. 1998 Jan;159(1):5-12 [9400426.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):230-4 [1376193.001]
  • [Cites] Lancet. 1991 Nov 16;338(8777):1271-2 [1682665.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17401-4 [1698775.001]
  • [Cites] Eur J Biochem. 1990 Dec 27;194(3):755-63 [1702714.001]
  • [Cites] Biochemistry. 1991 Feb 12;30(6):1723-30 [1704258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70 [2422647.001]
  • [Cites] Biochim Biophys Acta. 1988 Nov 17;967(2):158-62 [3263884.001]
  • [Cites] Eur J Biochem. 1987 Dec 30;170(1-2):111-20 [3691515.001]
  • [Cites] J Biol Chem. 1981 Aug 10;256(15):8134-9 [6167573.001]
  • [Cites] Biochim Biophys Acta. 1982 May 27;716(2):151-7 [6178438.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Sep 17;123(2):482-8 [6385967.001]
  • [Cites] Lab Invest. 1994 Dec;71(6):792-812 [7528831.001]
  • [Cites] J Biol Chem. 1995 Aug 4;270(31):18700-9 [7543108.001]
  • [Cites] Cancer. 1993 Aug 1;72(3 Suppl):1050-5 [7687518.001]
  • [Cites] Prostate Suppl. 1996;7:64-9 [8950366.001]
  • [Cites] Prostate. 1998 May;35(2):135-43 [9568677.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6958-63 [11559576.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):163-8 [12806377.001]
  • [Cites] Rev Urol. 2000;2 Suppl 4:S5-9 [16986040.001]
  • [Cites] Biochemistry. 1979 Feb 20;18(4):690-3 [84683.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):841-5 [1371559.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] J Urol. 1990 Dec;144(6):1523-6 [1700162.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):222-6 [1703033.001]
  • [Cites] FEBS Lett. 1987 Apr 20;214(2):317-22 [2436946.001]
  • [Cites] J Biol Chem. 1987 Jul 25;262(21):10035-8 [3611052.001]
  • [Cites] J Biol Chem. 1985 Feb 25;260(4):2432-6 [3919001.001]
  • [Cites] Urology. 2000 Apr;55(4):560-3 [10736503.001]
  • [Cites] Annu Rev Med. 2002;53:355-68 [11818479.001]
  • [Cites] Clin Chem. 2004 Jun;50(6):1017-25 [15054080.001]
  • [Cites] Pediatr Res. 1982 Aug;16(8):613-20 [6180371.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 1):1358-68 [7523702.001]
  • [Cites] Clin Chem. 1995 Nov;41(11):1567-73 [7586544.001]
  • [Cites] Can J Oncol. 1994 Nov;4 Suppl 1:65-9 [8853493.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1195-200 [1371233.001]
  • (PMID = 19636406.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713450
  • [Keywords] NOTNLM ; PSA / activation peptide / prostate cancer
  •  go-up   go-down


89. Hameed O, Humphrey PA: Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol; 2006 Jul;19(7):899-906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
  • Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.
  • The presence and diagnostic significance of stratified cells within non-cribriform carcinomatous prostatic glands has not been well addressed.
  • The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.
  • These cases were identified from needle biopsy cases from the consultation files of one of the authors and from a review of 150 consecutive in-house needle biopsy cases of prostatic adenocarcinoma.
  • The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.
  • The AMACR staining profile of the stratified foci was variable, with 4 foci showing positivity, and 3 foci being negative, including two cases that displayed AMACR positivity in adjacent non-stratified prostatic adenocarcinoma.
  • Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.
  • Recognition of this pattern of prostatic adenocarcinoma is necessary to correctly diagnose such cases as invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607376.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


90. Gilbert AM, Nowak P, Brooijmans N, Bursavich MG, Dehnhardt C, Santos ED, Feldberg LR, Hollander I, Kim S, Lombardi S, Park K, Venkatesan AM, Mallon R: Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett; 2010 Jan 15;20(2):636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Representative compounds showed activity in a cellular proliferation assay against Caco-2 colorectal, LoVo colorectal and PC3MM2 prostate adenocarcinoma cancer cells.

  • BindingDB. BindingDB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19969455.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Purines; 0 / Pyrazoles; 0 / Pyridines; 0 / pyrazolopyridine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


91. Engstrom C: Hot flashes. Clin J Oncol Nurs; 2006 Aug;10(4):533-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • J is a 68-year-old African American man with a history of advanced prostate cancer.
  • He was diagnosed nine months prior with adenocarcinoma of the prostate, with a Gleason score of 9 and tumor, node, metastasis staging of T3 NO M1.
  • His prostate-specific antigen (PSA) was 483 ng/ml at the time of diagnosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / adverse effects. Anilides / adverse effects. Antineoplastic Agents / adverse effects. Hot Flashes / chemically induced. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927907.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


92. Rabah DM, Arafa MA: Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer Prostatic Dis; 2010 Jun;13(2):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer screening in a Saudi population: an explanatory trial study.
  • The aim of this study is to explore the actual situation of prostate cancer in a cohort of healthy population in Saudi Arabia and to show the feasibility of screening for this disease using the internationally agreed criteria.
  • When either test was abnormal, transrectal ultrasound and multiple prostatic biopsies were performed for confirmation of the results.
  • Fifty two subjects had a positive diagnosis of prostatic adenocarcinoma, which compromised 2.5% of the cohort studied.
  • The cancer in 27 (52%) persons was organ confined, whereas in 14 (26.9%), it was metastatic.
  • The prevalence rate of prostate cancer detected by screening was higher than expected and the disease was advanced.
  • [MeSH-major] Biomarkers, Tumor / blood. Early Detection of Cancer / methods. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Digital Rectal Examination. Humans. Male. Middle Aged. Prostate / pathology. Saudi Arabia / epidemiology


93. Schmid HP, Engeler DS, Pummer K, Schmitz-Dräger BJ: Prevention of prostate cancer: more questions than data. Recent Results Cancer Res; 2007;174:101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of prostate cancer: more questions than data.
  • Established risk factors for prostatic adenocarcinoma include increasing age, ethnical origin (race), and familial/hereditary factors.
  • Pathological studies support the fact that geographic differences in incidence and prevalence do not stem from genetic variations as men with the same genetic background raised in different environments present the risk of prostate cancer associated with their country of residency.
  • Prostate cancer is basically an ideal candidate for exogenous preventive measures, such as dietary and pharmacological prevention, due to some specific features: high prevalence, long latency, endocrine dependency, availability of serum markers (prostate-specific antigen) and histological precursor lesions (prostatic intraepithelial neoplasia).
  • However, several large randomized trials are ongoing to clarify the potential for successful prostate cancer prevention.
  • Until we have the results, lifestyle changes could be recommended to men at risk for developing clinical prostate cancer and 5-alpha-reductase inhibitors need to be discussed with men who are concerned about prostate cancer.
  • [MeSH-major] Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302190.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


94. Radosavljevic R, Hadzi-Djokic J, Acimovic M, Tulic C, Dzamic Z, Djokic M, Micic S: Histopathological evaluation of radical prostatectomy in the treatment of localized prostate cancer. Acta Chir Iugosl; 2005;52(4):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological evaluation of radical prostatectomy in the treatment of localized prostate cancer.
  • Incidence of prostate cancer has risen dramatically in the past decade.
  • Radical prostatectomy is indicated in patients who have disease localized to the prostate.
  • The aim of the study is to make histopathological evaluation of radical prostatectomy in the treatment local prostate cancer.
  • Authors analyzed 49 cases of radical prostatectomy due to cancer localized to the prostate in period 1996-2000 in Clinic of Urology in Clinical Center of Serbia, Belgrade.
  • Radical prostatectomy is most adequate method in surgical treatment cancer localized in the prostate.
  • Pelvic lymphadenectomy is necessary for staging purposes in adenocarcinoma of the prostate.
  • Early detection adenocarcinoma of the prostate is important factor in decreasing rate of death.
  • [MeSH-major] Prostatectomy. Prostatic Neoplasms / surgery


95. Wang T, Chen YH, Hong H, Zeng Y, Zhang J, Lu JP, Jeansonne B, Lu Q: Increased nucleotide polymorphic changes in the 5'-untranslated region of delta-catenin (CTNND2) gene in prostate cancer. Oncogene; 2009 Jan 29;28(4):555-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased nucleotide polymorphic changes in the 5'-untranslated region of delta-catenin (CTNND2) gene in prostate cancer.
  • Cancer pathogenesis involves multiple genetic and epigenetic alterations, which result in oncogenic changes in gene expression. delta-Catenin (CTNND2) is overexpressed in cancer, although the mechanisms of its upregulation are highly variable.
  • Here we report that in prostate cancer, the methylation of CpG islands in the delta-catenin promoter was not a primary regulatory event.
  • However, using the single-strand conformation polymorphism analysis, we observed the increased nucleotide changes in the 5'-untranslated region of delta-catenin gene in human prostate cancer.
  • At least one such change (-9 G>A) is a true somatic point mutation associated with a high Gleason's score, poorly differentiated prostatic adenocarcinoma.
  • Laser capture microdissection coupled with PCR analyses detected the mutation only in cancerous but not in the adjacent benign prostatic tissues.
  • This is the first report of delta-catenin gene mutation in cancer and supports the notion that multiple mechanisms contribute to its increased expression in carcinogenesis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Feb 16;25(7):1090-8 [16247466.001]
  • [Cites] Int J Mol Med. 2006 Jan;17(1):159-70 [16328025.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9809-17 [17047041.001]
  • [Cites] Dev Biol. 2006 Dec 15;300(2):647-55 [16973151.001]
  • [Cites] Mol Carcinog. 2008 Feb;47(2):148-56 [17849422.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 2;369(2):414-20 [18302937.001]
  • [Cites] Genomics. 2000 Jan 15;63(2):157-64 [10673328.001]
  • [Cites] J Comp Neurol. 2000 May 1;420(2):261-76 [10753311.001]
  • [Cites] Nat Med. 2001 Jul;7(7):840-6 [11433350.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):667-73 [11477576.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4596-600 [11494157.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):228-37 [12115574.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2359-67 [15073112.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):63-9 [15215162.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):394-8 [8433392.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5579-83 [7923200.001]
  • [Cites] Neuroreport. 1997 May 27;8(8):2085-90 [9223106.001]
  • [Cites] Differentiation. 1997 Aug;61(5):293-304 [9342840.001]
  • [Cites] Neuroreport. 1999 Feb 25;10(3):563-8 [10208590.001]
  • [Cites] J Cell Biol. 1999 Feb 8;144(3):519-32 [9971746.001]
  • [Cites] Exp Cell Res. 1999 Aug 1;250(2):452-64 [10413599.001]
  • [Cites] Am J Med Genet. 1999 Sep 3;86(1):66-70 [10440832.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9 [10462204.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):39-46 [15628907.001]
  • [Cites] Clin Chem. 2005 Mar;51(3):649-52 [15738520.001]
  • [Cites] Am J Med Genet A. 2005 Aug 1;136A(4):381-5 [16001443.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1037-48 [16226102.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):219-25 [16595147.001]
  • (PMID = 18978817.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111891; United States / NCI NIH HHS / CA / R01 CA111891-02; United States / NCI NIH HHS / CA / R01 CA111891-03; United States / NCI NIH HHS / CA / CA111891
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Armadillo Domain Proteins; 0 / Catenins; 0 / Nerve Tissue Proteins; 0 / delta catenin
  • [Other-IDs] NLM/ NIHMS70249; NLM/ PMC2678952
  •  go-up   go-down


96. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • Immunohistochemistry for prostate-specific antigen (PSA), prostate specific acid phosphatase (PSAP), P501S (prostein), and prostate specific membrane antigen (PSMA) was performed, and moderate to strong immunoreactivity was considered a positive result.
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Acid Phosphatase. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Membrane Proteins / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Protein Tyrosine Phosphatases / biosynthesis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


97. Rai RS, Deb P, Rai R, Gupta E, Panayach JS: Synchronous primary triple neoplasia (renal cell carcinoma and prostate cancer in combination with thyroid neoplasm). Report of an unusual case. Minerva Urol Nefrol; 2007 Dec;59(4):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary triple neoplasia (renal cell carcinoma and prostate cancer in combination with thyroid neoplasm). Report of an unusual case.
  • We report a very rare case of triple primary neoplasia synchronously originating in the prostate, kidney and thyroid, in a 79-year-old male who presented with hematuria and continuous pain at the right hip.
  • Examination revealed an enlarged nodular thyroid, while digital rectal examination showed prostatic enlargement with elevated PSA (16.7 ng/mL).
  • Biopsies from prostate showed adenocarcinoma, along with deposits in ischial biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Follicular / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary. Prostatic Neoplasms / pathology. Thyroid Neoplasms / pathology


98. Gabril MY, Duan W, Wu G, Moussa M, Izawa JI, Panchal CJ, Sakai H, Xuan JW: A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Mol Ther; 2005 Mar;11(3):348-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
  • Preclinical studies of prostate cancer (CaP) have employed a genetically engineered mouse model, since there is no naturally occurring CaP in rodents.
  • We have previously reported a new knock-in mouse adenocarcinoma prostate (KIMAP) model.
  • KIMAP mice showed a balanced distribution of tumor extent, which penetrated the prostate gland.
  • [MeSH-major] Adenocarcinoma / genetics. Disease Models, Animal. Prostatic Neoplasms / genetics
  • [MeSH-minor] Animals. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Mice. Oligonucleotide Array Sequence Analysis. Prostate / pathology. Prostatic Secretory Proteins / genetics. Prostatic Secretory Proteins / metabolism


99. Pérez-Guillermo M, Acosta-Ortega J, García-Solano J: Pitfalls and infrequent findings in fine-needle aspiration of the prostate gland. Diagn Cytopathol; 2005 Aug;33(2):126-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pitfalls and infrequent findings in fine-needle aspiration of the prostate gland.
  • Based on the experience accumulated over two decades and in more than 7,000 transrectal fine-needle aspirations (FNAs) of the prostate gland, several benign and malignant unusual cytologic findings are described.
  • Infrequent benign cytologic findings and possible pitfalls are atrophic prostatic epithelium, squamous metaplasia, transitional cells, granulomatous prostatitis, seminal vesicle epithelium, ganglion cells, lubricant artifacts, and treatment effects.
  • Infrequent variants of carcinoma are foamy-cell carcinoma, prostatic duct adenocarcinoma, mucinous adenocarcinoma, transitional-cell carcinoma, small-cell carcinoma, squamous-cell carcinoma of the prostate, metastatic solid tumor within the prostate, and mesenchymal tumors.
  • Cytopathologists must be able to diagnose these variants of prostate adenocarcinoma because on most occasions the variants imply a worse clinical prognosis.
  • FNA of the prostate provides in a matter of minutes useful information concerning clinical management, prognosis, and treatment of patients.
  • [MeSH-major] Prostatic Neoplasms / pathology. Prostatitis / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Humans. Male. Prognosis. Prostate. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007671.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Kelović VL, Buković D, Badzek S, Curić Z, Kelović Z, Persec Z, Pavić M: Sex or surgery--erectile dysfunction after radical treatment of localized prostate cancer. Coll Antropol; 2009 Jun;33(2):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex or surgery--erectile dysfunction after radical treatment of localized prostate cancer.
  • The maintenance of satisfactory quality of life is major concern in majority of patients who elect treatment for localized prostate cancer.
  • Study population consisted of series of 57 patients with early-stage adenocarcinoma of the prostate, treated in our institution in the period from January 2003 till December 2003.
  • [MeSH-major] Erectile Dysfunction / epidemiology. Postoperative Complications / epidemiology. Prostatectomy / statistics & numerical data. Prostatic Neoplasms






Advertisement